↓ Skip to main content

The burden of congenital hyperinsulinism in the United Kingdom: a cost of illness study

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter
14 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The burden of congenital hyperinsulinism in the United Kingdom: a cost of illness study
Published in
Orphanet Journal of Rare Diseases, July 2018
DOI 10.1186/s13023-018-0867-6
Pubmed ID
Authors

Sana Eljamel, Annabel Griffiths, Jenni Evans, Indraneel Banerjee, Khalid Hussain, Richard Thompson

Abstract

Congenital hyperinsulinism (CHI) is a rare, genetic disease which causes persistent hypoglycaemia, typically in new-borns. Patients with the diffuse disease variant often require near-total surgical removal of the pancreas, causing insulin-dependent diabetes mellitus (IDDM). The CHI economic burden is currently unknown. This study aimed to estimate the annual cost of illness (COI) of CHI patients in the UK from a service provider perspective (National Health Service, NHS and Personal Social Services), and to explore cost distribution within the patient population. The model was based on standard practice of two CHI centres of excellence. Model inputs were informed by a pragmatic literature review, NHS Reference Costs (2015-2016) and the British National Formulary (2017). Only direct costs to the NHS and Personal Social Services were considered. A prevalence-based approach was used and annual costs incurred at all ages were calculated. A deterministic sensitivity analysis (DSA; run at 10%) identified major cost drivers. The COI of CHI patients to the NHS was £3,408,398.59 annually and average cost per patient was £2124.95. Cost distribution was skewed among CHI patients, with 5.9% of patients (95 patients in their first year of life) contributing to 61.8% (£2,105,491.07) of total costs. DSA results identified lack of response to first-line therapy and IDDM development post surgery (and associated healthcare costs) as major cost drivers. Despite its rare disease status, estimated annual costs of CHI to the NHS were substantial. Development and management of post-surgical IDDM as a major cost driver highlights the need for effective treatments to mitigate such consequences and costs.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 20%
Student > Master 5 13%
Student > Bachelor 5 13%
Other 3 8%
Lecturer 2 5%
Other 7 18%
Unknown 10 25%
Readers by discipline Count As %
Medicine and Dentistry 14 35%
Nursing and Health Professions 5 13%
Economics, Econometrics and Finance 5 13%
Immunology and Microbiology 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 3 8%
Unknown 11 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2018.
All research outputs
#1,525,533
of 13,668,760 outputs
Outputs from Orphanet Journal of Rare Diseases
#187
of 1,501 outputs
Outputs of similar age
#49,563
of 268,634 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#1
of 3 outputs
Altmetric has tracked 13,668,760 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,501 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,634 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them